Clinical Trials Directory

Trials / Sponsors / pharmaand GmbH

pharmaand GmbH

Industry · 22 registered clinical trials.

StatusTrialPhaseStarted
CompletedCATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer, Epithelial Ovarian Cancer
Phase 32021-03-22
TerminatedA Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
Solid Tumor
Phase 22020-01-16
CompletedStudy of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patien
Metastatic Castration Resistant Prostate Cancer
Phase 12019-12-05
CompletedA Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat
Multiple Myeloma
2019-11-04
TerminatedA Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Phase 22019-08-23
TerminatedA Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (
Ovarian Cancer, Triple-negative Breast Cancer, Urothelial Carcinoma
Phase 1 / Phase 22019-06-28
CompletedDrug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives
Neoplasms
Phase 12019-04-25
TerminatedRucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma
Phase 22018-06-01
Active Not RecruitingA Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Respo
Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer
Phase 32018-05-14
CompletedRucaparib Hepatic Impairment Study in Patients With a Solid Tumor
Neoplasms
Phase 12018-02-27
CompletedA Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor
Advanced Solid Tumor
Phase 12018-02-06
CompletedA Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant
Metastatic Castration Resistant Prostate Cancer
Phase 32017-06-13
CompletedARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Ca
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer
Phase 32017-03-01
CompletedA Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombina
Metastatic Castration Resistant Prostate Cancer
Phase 22017-02-15
CompletedAbsorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib
Solid Tumor
Phase 12016-11-01
CompletedPanobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma
Multiple Myeloma
Phase 22016-04-27
CompletedPharmacokinetic Drug-Drug Interaction Study of Rucaparib
Neoplasms
Phase 12016-04-01
CompletedPhase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Phase 32014-04-07
CompletedA Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Phase 22014-04-01
CompletedA Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian T
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer
Phase 22013-10-30
CompletedA Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phas
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Phase 1 / Phase 22011-11-01
CompletedA Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Reg
Advanced Solid Tumors
Phase 12010-02-01